Novo Nordisk has filed a federal lawsuit against Eli Lilly, accusing the company of misleading advertising for its GLP-1 drugs Zepbound and Mounjaro. Novo claims Lilly's ads use outdated data and unfairly compare Lilly's highest drug doses to lower doses of Novo's treatments, excluding newer data from higher-dose Wegovy versions. The lawsuit seeks to stop the ads, require corrections, and obtain damages. Eli Lilly defends its ads, citing direct clinical trial evidence, and vows to fight the lawsuit. This legal battle highlights intense competition in the weight-loss and diabetes drug market.
Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of running misleading ads that inaccurately claim superior efficacy of Lilly's obesity and diabetes drugs compared to Novo's. The lawsuit targets ads that use outdated clinical ...
Novo Nordisk's shares have risen about 27% due to strong commercial growth of oral Wegovy, which holds 89% of new U.S. prescriptions compared to Eli Lilly's 11%. Over 80% of these prescriptions are from new GLP-1 patients, expanding the market rather...
Citi has increased its price target for Novo Nordisk to DKK330 ahead of the company's Q2 results, citing strong sales from the Wegovy pill launch. The broker raised its 2026 sales and operating income estimates by 4-5%, and earnings per share forecas...
Novo Nordisk initiated a share repurchase program starting February 2026, aiming to buy back up to DKK 15 billion of B shares within 12 months. As of July 17, 2026, the company has repurchased approximately 24.96 million B shares at an average price ...
Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insuli...
